Journal
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
Volume 41, Issue 1, Pages 56-63Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MPH.0000000000001257
Keywords
pediatric; decision making; decision aids; treatment preference; hydroxyurea
Categories
Funding
- Agency for Healthcare Research and Quality's (AHRQ) Centers for Education and Research in Therapeutics (CERTs) [1U19HS021114]
- Health Resources and Services Administration (HRSA) Sickle Cell Disease Treatment Demonstration Program [U1EMC27863]
- Health Resources and Services Administration (HRSA) Sickle Cell Disease Treatment Demonstration Program Sickle Cell Disease Treatment Demonstration Program [HHSH25020100022C]
Ask authors/readers for more resources
National evidence-based guidelines recommend offering hydroxyurea to patients with sickle cell anemia 9 months of age and older using shared decision making, but offer no strategies to aid implementation. We developed a hydroxyurea multicomponent decision aid via a needs assessment, clinic observations, and iterative feedback to address parent decision needs and promote a discussion between clinicians and parents. A total of 75 parents and 28 clinicians participated across all phases. The decision aid was rated as useful. Hydroxyurea knowledge improved and decisional conflict decreased supporting the potential for use to facilitate shared decision making in pediatric sickle cell anemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available